Propranolol-Therapie bei infantilen Hämangiomen im Lid- und Orbitabereich

Zusammenfassung

Infantile Hämangiome im Lid- und Orbitabereich können trotz ihres selbstlimitierenden natürlichen Verlaufs zu funktionellen Defiziten infolge einer Amblyopie oder Optikuskompression führen oder ein ästhetisch störendes Erscheinungsbild entwickeln. Seit der „zufälligen“ Entdeckung des Effekts von Propranolol (unselektiver Betablocker) auf infantile Hämangiome im Jahr 2008 wird diese Substanz zur Behandlung komplizierter Hämangiome eingesetzt, die ansonsten den Einsatz von Kortikosteroiden, Laser oder operativen Verfahren erfordert hätten. Dargestellt werden Pathogenese, Klassifikation, Indikation zur Therapie, Therapieoptionen für infantile Hämangiome sowie eigene Ergebnisse nach systemischer Propranololtherapie bei Kindern mit therapiebedürftigen infantilen Hämangiomen im Lid- und Orbitabereich. Bei Bestätigung der bisherigen Daten hat Propranolol das Potenzial, die komplikationsträchtige medikamentöse Therapie von Hämangiomen im Lid- und Orbitabereich mit hochdosierten Kortikosteroiden und die chirurgische Therapie aufgrund einer deutlich günstigeren Nutzen-Risiko-Bilanz zu ersetzen. Weitere klinische Studien zur Optimierung von Dosierung, Behandlungsdauer, Art der Anwendung (lokal oder systemisch) sind jedoch erforderlich. Propranolol wird zukünftig bei komplizierten peri- und orbitalen Hämangiomen als Therapie der ersten Wahl unter pädiatrisch-kardiologischer Kontrolle eingesetzt werden.

Abstract

In spite of the self-limiting natural course of infantile haemangiomas of the eyelids and orbit, the effects of amblyopia, compression of the optic nerve, and impairment of the aesthetic appearance may develop. Since the serendipitous discovery of the effects of propranolol, a non-selective beta-blocker, on infantile haemangioma in 2008, it has largely replaced the former standard treatments with corticosteroids, laser or surgical procedures. This review discusses the pathogenesis, classification, indication for treatment, and treatment options for infantile haemangiomas. In addition, the results of patients with infantile haemangiomas of the eyelids and orbit treated with systemic propranolol are shown. With additional confirmation of data, including a positive effect-risk-analysis, propranolol will potentially replace high-dose corticosteroids and surgery in the treatment of infantile haemangiomas in the eyelids and orbit. Further clinical studies are necessary to optimise the dosage, treatment period, and application modalities (oral or topical). In the future, propranolol accompanied with paediatric-cardiological monitoring should emerge as the first-line therapy for problematic infantile haemangiomas.

Schlüsselwörter

infantile Hämangiome - Therapieoptionen - Propranolol - periorbitale und orbitale Hämangiome

Key words

infantile haemangiomas - therapeutic options - propranolol - periorbital and orbital haemangiomas

• Literatur

• 1 Holland KE, Drolet BA. Infantile hemangioma. Pediatr Clin North Am 2010; 57: 1069-1083
• 2 Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg 1983; 18: 894-900
• 3 Frieden IJ, Haggstrom AN, Drolet BA et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol 2005; 22: 383-406
• 4 Drolet B, Swanson EA, Frieden IJ et al. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008; 153: 712-715
• 5 Mulliken JB, Young AE. Vascular Birthmarks: Hemangiomas and Malformations. Philadelphia: WB Saunders; 1988: 41-45
• 6 Chang LC, Haggstrom AN, Drolet BA et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-367
• 7 Margileth AM, Museles M. Cutaneous hemangiomas in children: diagnosis and conservative management. JAMA 1965; 194: 523-526
• 8 Bauland CG, Lüning TH, Smit JM et al. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011; 127: 1643-1648
• 9 Boye E, Yu Y, Paranya G et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-752
• 10 Walter JW, North PE, Waner M et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosoms Cancer 2002; 33: 295-303
• 11 Höger PH. Hämangiome. Monatsschr Kinderheilkd 2011; 159: 1109-1118
• 12 Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots?. Arch Dermatol 2010; 146: 1295-1299
• 13 North PE, Waner M, Buckmiller L et al. Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovasc Path 2006; 15: 303-317
• 14 North PE, Waner M, Mizeracki A et al. GLUT-1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22
• 15 Herbert A, Ng H, Jessup W et al. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine-2,3 deoxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile hemangioma pathogenesis. Br J Dermatol 2011; 164: 234-235
• 16 Höger PH, Maerker JM, Kienast AK et al. Neonatal hemangiomatosis associated with placental chorioangiomas: report of three cases and review of the literature. Clin Exp Dermatol 2009; 34: e78-e80
• 17 Boon LM, Fishman SJ, Lund DP et al. Congenital fibrosarcoma masquerading as congenital hemangioma: report of two cases. J Pediatr Surg 1995; 30: 1378-1381
• 18 Boon LM, Enjolras O, Mulliken JB et al. Congenital hemangioma: evidence of accelerated involution. J Pediatr 1996; 128: 329-335
• 19 Mulliken JB, Bischoff J, Kozakewich HPW. Multifocal rapidly involuting congenital hemangioma: a link to chorangioma. Am J Med Genet A 2007; 143A: 3038-3046
• 20 Enjolras O, Mulliken JB, Boon LM et al. Noninvoluting congenital hemangioma: A rare cutaneous vascular anomaly. Plast Reconstr Surg 2001; 107: 1647-1654
• 21 Haik GR, Jakobiak FA, Ellsworth RM et al. Capillary hemangioma of the lids and orbit: an analysis of the clinical features and therapeutic results in 101 cases. Ophthalmology 1979; 80: 700-789
• 22 Rootman J, Marotta TR, Graeb DA. Vascular lesions. In: Rootman J ed. Diseases of the Orbit. 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 2003: 539-543
• 23 Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001; 27: 475-485
• 24 Haggstrom AN, Lammer EJ, Schneider RA et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006; 117: 698-703
• 25 Metry DW, Dowd CF, Barkovich AJ et al. The many faces of PHACE syndrome. J Pediatr 2001; 139: 117-123
• 26 Poetke M, Frommeld T, Berlien HP. PHACE syndrome: new views on diagnostic criteria. Eur J Pediatr Surg 2002; 12: 366-374
• 27 Margileth AM, Museles M. Cutaneous hemangiomas in children: diagnosis and conservative management. JAMA 1965; 194: 523-526
• 28 AWMF. Interdisziplinäre Leitlinie “Hämangiome im Säuglings- und Kleinkindesalter” (2007) der Deutschen Dermatologischen Gesellschaft, der AG Pädiatrische Dermatologie sowie der Deutschen Gesellschaften für Kinderchirurgie und Kinder- und Jugendmedizin. AWMF-Leitlinien-Register Nr. 013/051. Im Internet: http://www.paediatrische-dermatologie.de/uploads/pdf/0710haemang.pdf Stand: 24.9.2014
• 29 Millischer-Bellaïche AE, Enjolras O, André C et al. [Eyelid hemangiomas in infants: contribution of MRI]. J Radiol 2004; 85: 2019-2028
• 30 Schwartz SR, Kodsi SR, Blei F et al. Treatment of capillary hemangiomas causing refractive and occlusional amblyopia. J AAPOS 2007; 11: 577-583
• 31 Haggstrom AN, Drolet BA, Baselga E et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882-887
• 32 Robb RM. Refractive errors associated with hemangiomas of the eyelids and orbit in infancy. Am J Ophthalmol 1977; 83: 52-58
• 33 Stigmar G, Crawford JS, Ward CM et al. Ophthalmic sequelae of infantile hemangiomas of the eyelids and orbit. Am J Ophthalmol 1978; 85: 806-813
• 34 Bogan S, Simon J, Krohel GB et al. Astigmatism associated with adnexal masses in infancy. Arch Ophthalmol 1987; 105: 1368-1370
• 35 Morrell AJ, Willshaw HE. Normalisation of refractive error after steroid injection of adnexal hemangiomas. Br J Ophthalmol 1991; 75: 301-305
• 36 Deady JP, Willshaw HE. Vascular hamartomas in childhood. Trans Ophthalmol Soc U K 1986; 105: 712-716
• 37 Slaughter K, Sullivan T, Boulton J et al. Early surgical intervention as definitive treatment for ocular adnexal capillary hemangiomas. Clin Experiment Ophthalmol 2003; 31: 418-423
• 38 Ashinoff R, Geronemus RG. Flashlamp-pumped pulsed dye laser for port-wine stains in infancy: earlier versus later treatment. J Am Acad Dermatol 1991; 24: 467-472
• 39 Garden JM, Bakus AD. Laser treatment of port-wine stains and hemangiomas. Dermatol Clin 1997; 15: 373-383
• 40 Dummer R, Graf P, Greif C et al. Treatment of vascular lesions using the Versa Pulse variable pulse width frequency doubled neodymium : YAG laser. Dermatology 1998; 197: 158-161
• 41 Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr 1968; 72: 351-357
• 42 AWMF. Interdisziplinäre Leitlinie “Hämangiome im Säuglings- und Kleinkindesalter” (2012) der Deutschen Gesellschaften für Kinderchirurgie und Kinder- und Jugendmedizin, der Deutschen Dermatologischen Gesellschaft, der AG Pädiatrische Dermatologie und der Deutschen Gesellschaft für Mund-, Kiefer- und Gesichtschirurgie, AWMF-Leitlinien-Register Nr. 006/100. Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/006-100l_S2k_Haemangiome_112012-122014.pdf Stand: 24.9.2014
• 43 Barrio VR, Drolet BA. Treatment of hemangiomas in infancy. Dermatol Ther 2005; 18: 151-159
• 44 Kushner BJ. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. Plast Reconstr Surg 1985; 76: 517-526
• 45 OʼKeefe M, Lanigan B, Byrne SA. Capillary hemangioma of the eyelids and the orbit: a clinical review of the safety and efficacy of intralesional steroid. Acta Opthalmol Scand 2003; 81: 294-298
• 46 Verity DH, Rose GE, Restori M. The effect of intralesional steroid injections on the volume and blood flow in periocular capillary hemangiomas. Orbit 2008; 27: 41-47
• 47 Léautè-Labrèze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651
• 48 Lou Y, Peng WJ, Cao Y et al. The effectiveness of propranolol in treating infantile hemangiomas: A meta-analysis including 35 studies. Br J Clin Pharmacol 2014; 78: 44-57
• 49 Marqueling AL, Oza V, Frieden IJ et al. Propranolol and infantile hemangiomaas for years later: a systematic review. Pediatr Dermatol 2013; 30: 182-191
• 50 Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med 2008; 359: 2846
• 51 Bagazgoita L, Torrelo A, Guitierrez JC et al. Propranolol for infantile hemangiomas. Pediatr Dermatol 2011; 28: 108-111
• 52 Fuchsmann C, Quintal MC, Giguerre C et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg 2011; 137: 471-478
• 53 Bernabeau-Wittel J, Pereyra-Rodríguez JJ, Mantrana-Bermeja ME et al. [Propranolol for the treatment of severe hemangiomas of infancy: Results from a series of 28 patients.]. Actas Dermosifiliogr 2011; 102: 510-516
• 54 Schiestl C, Neuhaus K, Zoller S et al. Efficacy and safety of Propranolol as first-line treatment for infantile hemangiomas. Pediat Dermatol 2011; 28: 108-114
• 55 Moehrle M, Leaute-Lebreze C, Schmidt V et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013; 30: 245-249
• 56 Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010; 146: 564-565
• 57 Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128: 255-256
• 58 Khanger N, Pahwa M. Dramatic response of a large hemifacial infantile hemangioma associated with PHACE syndrome to topical timolol lotion. Br J Ophthalmol 2011; 164: 886-888
• 59 Chakkittakandiyil A, Phillips R, Frieden IJ et al. Timolol maleate 0,5 or 0,1 % gel-forming solution for infantile hemangiomas: a retrospective, multicenter cohort study. Pediatr Dermatol 2012; 29: 28-31
• 60 Barlow CF, Priebe CJ, Mulliken JB. Spastic diplegia as a complication of interferon alpha-2a treatment of hemangioma of infancy. J Pediatr 1998; 132: 527-530